Business Wire

STALLERGENES-GREER

27.5.2024 10:01:30 CEST | Business Wire | Press release

Share
Stallergenes Greer Foundation Announces Winners of 2023 Science Awards for Allergy

The Stallergenes Greer Foundation, dedicated to fostering innovation and precision medicine in the field of allergy, is delighted to announce the recipients of the 2023 edition of its prestigious Science Awards for Allergy. These awards recognise outstanding contributions to allergy research and environmental health initiatives and allocate up to €150,000 to support these efforts.

After thorough review of the 45 high-level applications by the Foundation’s Scientific Board and Managing Board, the following researchers have been selected as recipients:

Innovation Awards

  • Rising Talent Category:

Assoc. Prof. Jennifer Koplin, Group Leader, Childhood Allergy & Epidemiology, Child Health Research Centre, The University of Queensland, Australia, recognised for her research: Association between earlier introduction of peanut and prevalence of peanut allergy in infants in Australia” will receive €25,000.

Assoc. Prof. Rachel Peters, Principal Research Fellow, Murdoch Children's Research Institute, Australia, recognised for her research: “Multiple food allergy phenotypes in infancy are associated with lung function deficits and asthma at 6 years of age: a prospective cohort study in Australia” will receive €25,000.

  • Mid-Career Scientist Category:

Assoc. Prof. Jenny Hallgren Martinsson, Senior Lecturer in Immunology, Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden, recognized for her research: “Circulating mast cell progenitors increase during natural birch pollen exposure in allergic asthma patients” will receive €25,000.

Dr Luciana Kase Tanno, Researcher, University Hospital of Montpellier, France, recognised for her research: “Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases 11” will receive €25,000.

Environmental Health Award

Dr Dorra Gharbi, Post doctoral research fellow, Allergology and Immunology Unit, Lung Institute, University of Cape Town, South Africa, recognised for her research: “Allergenic tree pollen in Johannesburg and Cape Town as a public health risk: Towards a sustainable implementation framework for South African cities” will receive €50,000.

Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation, expresses his congratulations to the award recipients. “These researchers exemplify the spirit of innovation and dedication that the Stallergenes Greer Foundation seeks to promote. Their work not only advances our understanding of allergies but also brings us closer to creating healthier futures for all. These grants contribute to nurturing the next generation of researchers, in line with the foundation’s core mission of supporting academic endeavors aimed at fostering future leaders in allergy healthcare.

The Scientific Committee, composed of a panel of international renowned experts:

  • Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France)
  • Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, (Vatican City)
  • Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon)
  • Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.A.)

highlighted the comprehensive coverage of allergy research of these awards, spanning public health with international classification of diseases, clinical science in asthma, and epidemiology in food allergy and aerobiology. The members also noted that these awards present an outstanding opportunity to highlight the importance of allergy research while tackling the increasing prevalence of allergic disease across the globe.

The Stallergenes Greer Foundation extends its gratitude to all applicants and acknowledges the invaluable contribution of the Scientific Board in the selection process.

The next Science Awards will be announced in 2025.

About the research projects

Jennifer Koplin’s research uses large-scale population-based studies to advance the understanding of childhood food allergy. These studies contribute to the development of novel prevention interventions and are helping to target emerging prevention and treatment strategies for the individuals who will benefit most from these interventions. Her innovative work with the EarlyNuts study evaluated the uptake and impact of early peanut introduction on peanut allergy, not only showing that population-level changes in infant feeding practices are possible, but also contributing to reshaping clinical and public health guidelines, and inspiring novel clinical trials internationally.

Soriano VX, et al: Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia. JAMA. 2022 Jul 5;328(1):48-56. https://pubmed.ncbi.nlm.nih.gov/35788795/

Rachel Peters’ research aims to reduce the adverse consequences of infant food allergy – affecting up to 10% of children worldwide – on children’s future health. Through a pioneering study on the link between childhood food allergy and respiratory health, she uncovered that infants with food allergy, even if it resolves, present with lung function deficits and a higher risk of asthma by school age. These findings are sparking greater clinical vigilance regarding the monitoring of respiratory health of children with food allergies and will support clinicians worldwide in tailoring patient care.

Peters RL. Soriano VX, Lycett K, et al: Multiple food allergy phenotypes in infancy are associated with lung function deficits and asthma at 6 years of age: a prospective cohort study in Australia. The Lancet child & adolescent health 2023 Sep;7(9):636-647 .https://pubmed.ncbi.nlm.nih.gov/37506717/

Jenny Hallgren Martinsson’s research interest is to determine the role of mast cells—immune cells responsible for immediate allergic reactions—in allergic asthma. Her recent cutting-edge study on birch pollen-sensitized asthma patients and mast cell biology suggests that mast cell progenitors may play a pathogenic role in allergic asthma, thus paving the way for the development of new biomarkers and treatment targets for asthma.

P Abigail Alvarado-Vazquez et al, Circulating mast cell progenitors increase during natural birch pollen exposure in allergic asthma patients Allergy. 2023 Nov;78(11):2959-2968. doi: 10.1111/all.15860. Epub 2023 Aug 24 https://pubmed.ncbi.nlm.nih.gov/?term=Alvarado-Vazquez+PA&cauthor_id=37615432

Luciana Kase Tanno dedicated her career to epidemiology research to support public health and preventive actions, more particularly focusing on hypersensitivity conditions such as anaphylaxis. Leveraging a detailed academic and evidence-based action plan, her work helped in reviewing the current International Classification of Diseases to provide greater visibility to allergic and hypersensitivity conditions. Her efforts and commitment will further ensure that patients may benefit from the best management strategy throughout the world.

Kase Tanno et al, Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases 11.” J Allergy Clin Immunol. 2019 Sep;144(3):627-633. doi: 10.1016/j.jaci.2019.05.013. Epub 2019 Jun 20. https://pubmed.ncbi.nlm.nih.gov/31229269/

Dorra Gharbi’s research focuses on aerobiology, air quality and environmental health. Her transdisciplinary work is enhancing our understanding of how climate, environmental exposures (aeroallergens) and intrinsic factors intersect to impact respiratory health outcomes. Her efforts to investigate a phenomenon in a specific setting “allergenic pollen-producing trees within the context of urban green infrastructure in South African cities”, to inform a wider inquiry regarding the health risk for the South African population, as well as the management thereof in a sustainable implementation framework. The outcome of this research opens the possibility of designing early warning systems to predict community-level surges in poor respiratory health outcomes and be able to provide allergy management plans to prevent allergic reactions.

Gharbi, D., Neumann, F.H., Cilliers, S. et al. Allergenic tree pollen in Johannesburg and Cape Town as a public health risk: towards a sustainable implementation framework for South African cities. Discov Sustain 4, 32 (2023). https://doi.org/10.1007/s43621-023-00151-9

About the Stallergenes Greer Foundation

The Stallergenes Greer Foundation, under the aegis of the Fondation de France, is a non-profit foundation whose aim is to build healthier futures for all. The Stallergenes Greer Foundation pursues a comprehensive approach calling for “the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals and our environment”, as defined by the One Health initiative.

About the Fondation de France

Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity and translate them into effective actions of general interest. With close to 1,000 hosted foundations, the Fondation de France supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240527622781/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye